• Earlier in May 2026, Pfizer reported strong Phase 2 data for its investigational 25‑valent pneumococcal conjugate vaccine in infants and secured a European Commission approval to expand HYMPAVZI’s use to hemophilia A and B patients with inhibitors aged 12 and older.
• These updates strengthen Pfizer’s position in complex vaccines and rare hematology, highlighting how targeted innovation can broaden its addressable patient population.
• We’ll now examine how the Phase 2 pneumococcal results and HYMPAVZI label expansion could influence Pfizer’s wider investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe that its late stage pipeline in oncology, vaccines and rare diseases can offset patent expirations and pricing pressure over time. The new pneumococcal data and HYMPAVZI label expansion both support that pipeline story, but they do not change the key near term swing factors: execution on major oncology launches and how quickly patent and pricing headwinds show up in reported revenue.

Among recent updates, the expanded European approval for HYMPAVZI looks most connected to this story. It adds a differentiated option for a difficult hemophilia subgroup, reinforcing Pfizer’s push into higher value, specialist therapies that can sit alongside larger vaccine franchises. For investors, it ties directly into the current catalyst of converting late stage assets into durable, post patent cliff revenue while competition and policy pressures remain intense.

Yet behind these encouraging trial wins, investors still need to watch how patent expirations and drug price reforms could reshape Pfizer’s earnings power and dividend safety...

Pfizer's narrative projects $59.6 billion revenue and $12.8 billion earnings by 2028. This requires a 2.2% yearly revenue decline and about a $2.1 billion earnings increase from $10.7 billion today.

Uncover how Pfizer's forecasts yield a $29.08 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts were assuming Pfizer’s revenue would fall about 7.8 percent a year to roughly US$49,000,000,000 by 2029, so when you compare that backdrop to fresh wins like HYMPAVZI’s expansion, you can see how opinions can differ sharply and why it is worth weighing more than one view of Pfizer’s future.

Explore 22 other fair value estimates on Pfizer - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pfizer research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.